Filtered By:
Source: Annual Review of Medicine
Condition: Heart Failure
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 109 results found since Jan 2013.
Cardiovascular Effects of Incretin-Based Therapies.
This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as evidence that the incretin-based therapies have acceptable CV safety profiles for patients with T2DM. The studies differ with regard to patient population, trial duration, and heart failure outcomes but show similar findings for CV death, nonfatal myocardial infarction, and stroke, as well as hospitalization for unstable angina.
PMID: 26768240 [PubMed - in process]
Source: Annual Review of Medicine - January 14, 2016 Category: Journals (General) Authors: White WB, Baker WL Tags: Annu Rev Med Source Type: research
Hypertrophic Cardiomyopathy: New Concepts and Therapies
Annu Rev Med. 2022 Jan 27;73:363-375. doi: 10.1146/annurev-med-042220-021539.ABSTRACTHypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited myocardial disorder, transformed over the last several years into a treatable condition with the emergence of effective management options that alter natural history at all ages. Now available are a matured risk stratification algorithm selecting patients for prophylactic implantable defibrillators that prevent arrhythmic sudden death; low-risk, high-benefit surgical myectomy to reverse progressive heart failure symptoms due to left ventricula...
Source: Annual Review of Medicine - January 27, 2022 Category: General Medicine Authors: Barry J Maron Ethan J Rowin Martin S Maron Source Type: research
